<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602939</url>
  </required_header>
  <id_info>
    <org_study_id>EC11-187</org_study_id>
    <nct_id>NCT01602939</nct_id>
  </id_info>
  <brief_title>Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis</brief_title>
  <official_title>Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Virgen de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Virgen de la Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy in terms of clinical and biological
      response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with
      advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of therapy on bone marrow mast cell infiltration.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of bone marrow response will be assessed by immunohistochemestry, citology, flow cytometry and molecular analyses of bone marrow samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of therapy on serum tryptase levels and other altered peripheral blood parameters due to mastocytosis.</measure>
    <time_frame>6 months</time_frame>
    <description>Serum tryptase and any other mastocytosis-related altered biochemical parameter at diagnosis will be measured monthly until the end of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of therapy on mast cell-mediator release symptoms: pruritus, flushing, gastrointestinal symptoms or anaphylaxis).</measure>
    <time_frame>6 months</time_frame>
    <description>Specific questionnaires regarding mast cell-mediator release symptoms will be filled monthly by each patient until the end of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine de safety of combined therapy with low doses of cladribine plus pegylated interpheron alpha-2a.</measure>
    <time_frame>6 months</time_frame>
    <description>Potentially drugs-related adverse events will be recorded in each case following accepted criteria (NIH CTCAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of therapy on mastocytosis skin lesions.</measure>
    <time_frame>6 moths</time_frame>
    <description>Evaluation of cutaneous response will be assessed by macroscopic inspection including photographs and by skin immunohistochemestry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of therapy on mastocytosis-related organomegalies.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of organomegalies response will be assessed by abdominal ultrasound and/or computerized tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of therapy on mastocytosis-related bone alterations.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of bone response will be assessed by X-ray survey and/or computerized tomography.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Systemic Mastocytosis</condition>
  <arm_group>
    <arm_group_label>2CDA+IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine and pegylated interpheron alpha-2a</intervention_name>
    <description>Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.
Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months.</description>
    <arm_group_label>2CDA+IFN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years.

          -  Diagnosis of advanced systemic mastocytosis (aggressive systemic mastocytosis or
             proggressing systemic mastocytosis) with D816V or other exon 17 KIT mutations.

          -  ECOG ≤ 3.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Impaired liver function (total bilirubin ≥ 2.0 mg/dl, AST or ALT &gt; 3 x upper limit of
             normal)not related to mastocytosis.

          -  Impaired renal function (≥ 2.0 mg/dL)not related to mastocytosis.

          -  Grade III-IV cytopenias not related to mastocytosis. Severe cardiopathy (grade III/IV
             of NYHA, or left ventricular ejection fraction &lt; 50%).

          -  Pregnancy or breastfeeding.

          -  Female patients who do not use contraceptive methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Escribano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Estudios de Mastocitosis de Castilla La Mancha</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Escribano, MD, PhD</last_name>
    <phone>+34925269335</phone>
    <email>lescribanom@sescam.jccm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iván Alvarez-Twose, MD</last_name>
    <phone>+34925269336</phone>
    <email>ivana@sescam.jccm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Escribano, MD, PhD</last_name>
      <phone>+34925269335</phone>
      <email>lescribanom@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Iván Alvarez-Twose, MD</last_name>
      <phone>+34925269336</phone>
      <email>ivana@sescam.jccm.es</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Escribano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iván Alvarez-Twose, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Virgen de la Salud</investigator_affiliation>
    <investigator_full_name>LUIS ESCRIBANO</investigator_full_name>
    <investigator_title>Director of the Instituto de Estudios de Mastocitosis de Castilla La Mancha</investigator_title>
  </responsible_party>
  <keyword>Mast cell</keyword>
  <keyword>Mastocytosis</keyword>
  <keyword>Mast cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

